17-10-1-2 ⓔ文献

  1. Dale DC: Neutropenia and neutrophilia. Williams Hematology, seventh edition (Lichtman MA, Kipps TJ, et al eds), McGraw–Hill, Medical Publication Division, 2006; 907–916.

  2. Pei XH, Nakanishi Y, et al: Granulocyte, granulocyte–macrophage, and macrophage colony–stimulating factors can stimulate the invasive capacity of human lung cancer cells. Br J Cancer 1999; 79: 40–46.

  3. Nagata S, Tsuchiya M, et al: Molecular cloning and expression of cDNA for humangranulocyte colony–stimulating factor. Nature, 1986; 319: 415–418.

  4. Nelson S: Role of granulocyte colony–stimulating factor in the immune response to acute bacterial infection in the nonneutropenic host: an overview. Clin Infect Dis, 1994; 18 Suppl2: S197–204.

  5. Nishimoto N, Terao K, et al: Mechanisms and pathologic significances in increase in serum interleukin–6 (IL–6) and soluble IL–6 receptor after administration of an anti–IL–6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood, 2008; 112: 3959–3964.

  6. Pardanani A, Brockman SR, et al: FIP1L1–PDGFRA fusion. Prevalence and clinicopathologic correlates in 89 consective patients with moderate to severe eosinophilia. Blood, 2004; 104: 3038–3045.

  7. Isobe Y, Tomomatsu J, et al: Diagnostic problems among chronic lymphocytic leukemia and other indolent B–cell leukemias in a Japanese population. Intern Med, 2012; 51: 1977–1981.